Impact of Anti-CD20 Antibodies on the Incidence of Secondary Cancers in Patients Treated for Chronic Lymphocytic Leukemia

被引：0
|
作者：
Guidez, Stephanie [1 ]
Demarquette, Helene [1 ]
Nudel, Morgane [1 ]
Le Grand, Charline [2 ]
Boyle, Eileen [1 ]
Herbaux, Charles [1 ]
Facon, Thierry [1 ]
Cazin, Bruno [1 ]
Morschhauser, Franck [1 ]
机构：
[1] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France
[2] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparison of Cytotoxic Mechanism's of Anti-CD20 Antibodies GA101 and Rituximab Against Fresh Chronic Lymphocytic Leukemia Cells
    Reslan, Lina
    Dalle, Stephane
    Tournebize, Cindy
    Herveau, Stephanie
    Cros, Emeline
    Dumontet, Charles
    BLOOD, 2010, 116 (21) : 1025 - 1025
  • [32] Treatment of severe chronic lymphocytic leukemia in residual disease stage with autologous macrophages activated and associated to humanized anti-CD20 antibodies.
    Sutton, L
    Cazin, B
    Azar, N
    Baudet, S
    Tardy, D
    Romet-Lemonne, JL
    Maloum, K
    BLOOD, 2000, 96 (11) : 295B - 295B
  • [33] Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
    Zelenetz, Andrew David
    Mato, Anthony R.
    Robak, Tadeusz
    Jones, Jeffrey Alan
    Pagel, John M.
    Barrientos, Jacqueline Claudia
    Brown, Jennifer R.
    Montillo, Marco
    Kipps, Thomas J.
    Dubowy, Ronald
    Xing, Guan
    Li, Julia
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 285B - 285B
  • [35] CHANGES IN SERUM COMPLEMENT ACTIVITY DURING ANTI-CD20 AND ANTI-CD52 MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Stasilojc, Grzegorz
    Felberg, Anna
    Taszner, Michal
    Urban, Aleksandra
    Ma, Shuo
    Blom, Anna
    Lundin, Jeanette
    Osterborg, Anders
    Okroj, Marcin
    MOLECULAR IMMUNOLOGY, 2019, 114 : 415 - 415
  • [36] Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
    Lauria, F
    Lenoci, M
    Annino, L
    Raspadori, D
    Marotta, G
    Bocchia, M
    Forconi, F
    Gentili, S
    La Manda, M
    Marconcini, S
    Tozzi, M
    Baldini, L
    Zinzani, PL
    Foà, R
    HAEMATOLOGICA, 2001, 86 (10) : 1046 - 1050
  • [37] CHARACTERIZATION OF A PATIENTS' ANTIBODIES TO THE ANTI-CD20 THERAPEUTIC RITUXIMAB
    Mahadik, Younis
    Young, Stephen
    Morgan, Matthew
    Gordon, Caroline
    Harper, Lorraine
    RHEUMATOLOGY, 2012, 51 : 142 - 143
  • [38] Depletion of Chronic Lymphocytic Leukemia Cells From Whole Blood Samples Mediated by the Anti-CD20 Antibodies Rituximab and GA101
    Patz, Michaela
    Forcob, Nche
    Mueller, Bianka
    Klein, Christian
    Umana, Pablo
    Hallek, Michael
    Krause, Guenter
    BLOOD, 2009, 114 (22) : 934 - 934
  • [39] Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Ogura, Michinori
    Hatake, Kiyohiko
    Tobinai, Kensei
    Uchida, Toshiki
    Suzuki, Tatsuya
    Terui, Yasuhito
    Yokoyama, Masahiro
    Maruyama, Dai
    Mori, Masakazu
    Jewell, Roxanne C.
    Katsura, Koichi
    Hotta, Tomomitsu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 466 - 475
  • [40] Orphan-drug status granted to new anti-CD20 monoclonal antibody for chronic lymphocytic leukemia
    不详
    IMMUNOTHERAPY, 2010, 2 (01) : 7 - 7
12345